Targeted Therapy for Colorectal Cancer

Targeted therapy for colorectal cancer has changed how doctors treat this disease. Instead of using only chemotherapy, doctors now use medicines that aim at specific molecules involved in cancer growth. These targeted drugs work differently from chemotherapy by focusing only on cancer cells and leaving healthy cells mostly unharmed.

Key Mechanisms in Targeted Therapy

The FDA approves many targeted therapies to treat colorectal cancer. They give hope, especially for advanced colorectal cancer. As researchers study clinical trials, more treatments are becoming available. In this article, we’ll explain how targeted therapy works, the important drugs, and why keywords like blood vessel, microsatellite instability (MSI), BRAF mutations, and more matter in treatment. Additionally, terms such as signal transducer and drug administration FDA approved targeted therapies,

human epidermal growth factor receptor (EGFR), and resistance to anti-EGFR therapy play an essential role in understanding and advancing treatment options.

How Targeted Therapy Works

Blood Vessel and Tumor Growth

Cancer needs nutrients to grow. It gets these nutrients by making new blood vessels through a process called angiogenesis. Drugs that stop blood vessel growth can starve the tumor. One major target for this is the vascular endothelial growth factor (VEGF). By blocking VEGF, doctors can prevent tumors from growing bigger. Some drugs block VEGF directly or block the VEGF receptor on cells.

Endothelial Growth Factor VEGF

The endothelial growth factor VEGF is essential for blood vessel growth. Targeted drugs that attack VEGF prevent new vessels from forming. Without new blood vessels, tumors cannot get enough oxygen and nutrients. That slows down or even stops their growth.

Important Genes in Targeted Therapy

Microsatellite Instability (MSI)

Some colorectal cancers have something called microsatellite instability (MSI). This happens when the cells’ DNA repair system is broken. Tumors with MSI often respond better to immune-based therapies. Doctors test for MSI to find the best treatment plan.

BRAF Mutations

Another important genetic change in colorectal cancer is BRAF mutations. Patients with these mutations often have a poorer outlook. Special drugs now exist to target these mutations. Knowing if a cancer has a BRAF mutation can help choose better treatments.

KRAS Mutated

The KRAS mutated gene is also crucial. If colorectal cancer has a KRAS mutation, certain treatments may not work. That’s why doctors always test for KRAS before starting anti-EGFR therapy.

Why Choose Targeted Therapy for Colorectal Cancer?

Targeted therapy offers important advantages compared to traditional treatments. Here are three key reasons to choose it:

Focused Attack on Cancer Cells

Targeted therapy is designed to attack only cancer cells, not healthy ones. It blocks specific proteins or genes like VEGF, EGFR, or BRAF mutations that help cancer grow. This focused action helps reduce side effects compared to treatments like chemotherapy.

Personalized Treatment Plans

Many targeted drugs are chosen based on the patient’s specific cancer features, such as KRAS mutated status or microsatellite instability (MSI). This makes treatment more personal and more effective. It ensures that patients get the therapies most likely to work for their cancer type.

New Hope When Other Treatments Fail

For patients with chemotherapy refractory metastatic colorectal cancer, targeted therapy offers new hope. Medicines that target specific cancer markers or treatments using the immune system provide options even after standard treatments stop working.

Types of Targeted Therapy for Colorectal Cancer

There are different types of targeted therapy used in advanced colorectal cancer. Some focus on blood vessels, others on proteins or genes inside cancer cells. Here are the major types:

Anti-VEGF Therapy

Anti-VEGF therapy blocks vascular endothelial growth factor (VEGF), a protein that helps form new blood vessels. Tumors need these blood vessels to grow and spread. By stopping VEGF, tumors are starved of oxygen and nutrients, slowing their growth.

Targeted drugs approved by the FDA focus on VEGF to treat advanced colorectal cancer. This therapy can help patients live longer and improve symptoms. However, side effects like high blood pressure, bleeding, and slower wound healing can happen because VEGF affects normal tissues too.

Clinical trials are testing new ways to improve anti-VEGF therapy, including combining it with other treatments. Blocking blood supply is a strong strategy that directly weakens the tumor without damaging the whole body.

Anti-EGFR Therapy

Anti-EGFR therapy targets the epidermal growth factor receptor (EGFR) on cancer cells. EGFR helps cancer cells grow quickly. Blocking it slows tumor growth and sometimes shrinks tumors.

Studies compare different approaches for patients with chemotherapy refractory metastatic colorectal cancer to find the best choice. Testing is important because patients with a KRAS mutated gene often don’t benefit from this therapy.

Skin rash is a common side effect because EGFR also exists in healthy skin cells. Despite this, anti-EGFR therapy offers new hope for patients whose cancers no longer respond to chemotherapy.

Targeting Gene Mutations

Some targeted therapies focus on specific gene mutations like BRAF mutations and KRAS mutated cancers. These gene changes cause cells to grow abnormally.

Special therapies block the bad signals caused by mutations, slowing cancer growth. Patients are tested for these mutations to decide which targeted drugs are best.

New treatments are also being developed through clinical trials. Targeting gene mutations gives patients more options, especially when standard treatments stop working. It is an important step toward personalized cancer care.

Immune System Help

Some targeted therapies work by helping the immune system fight cancer. Normally, cancer cells hide from the immune system. New therapies use processes like antibody-dependent cell-mediated cytotoxicity to reveal cancer cells and help immune cells kill them.

This type of therapy works especially well for cancers with microsatellite instability (MSI), where tumors have many mutations. By boosting the immune system, these therapies offer a new way to attack cancer without harming normal cells.

Researchers are exploring better ways to combine immune therapy with targeted drugs to treat advanced colorectal cancer more effectively.

Hope for the Future

Clinical Trials

Today, numerous clinical trials are underway to discover more effective treatments for colorectal cancer. These trials are essential for testing innovative therapies, such as targeted drugs, combination treatments, and immunotherapies. By participating in clinical trials, patients gain access to the latest treatments that may not yet be available outside of research settings. This provides hope for better outcomes and advanced treatment options for those battling colorectal cancer.

Cancer Includes Many Targets

Modern cancer therapies focus on multiple targets within the body to fight cancer more effectively. These targets include factors like blood vessel growth, gene mutations such as KRAS and BRAF, and immune checkpoints. By addressing these diverse aspects of cancer, doctors can increase the likelihood of successfully managing the disease. The ability to target various mechanisms of cancer gives physicians a broader toolkit to fight cancer on multiple fronts, improving the chances of controlling its progression.

Targeted Drugs for Advanced Colorectal Cancer

For patients with advanced colorectal cancer, targeted therapies have become a crucial part of treatment. These therapies focus directly on cancer cells, sparing much of the healthy tissue and reducing side effects compared to traditional treatments. Doctors use them to interrupt specific signals that tumors need to grow and spread.

Without these targeted treatments, patients facing advanced or metastatic disease would have far fewer options and a much more challenging outlook. Thanks to ongoing advancements, many patients now live longer and enjoy a better quality of life even after a diagnosis of metastatic colorectal cancer. Researchers continue to refine these therapies, finding new ways to make treatment even more effective and to offer hope to more people battling this disease.

Combining Therapies for Better Results

The combination of different treatment approaches, such as combining targeted therapies with chemotherapy or immunotherapy, is an emerging strategy in colorectal cancer treatment. This approach allows doctors to attack cancer cells from multiple angles, making it more challenging for tumors to adapt and survive. By pairing therapies, the body can leverage different mechanisms to fight cancer, enhancing the overall effectiveness of treatment and offering patients a better chance for long-term survival.

Doctors carefully select combinations based on the cancer’s specific genetic profile and behavior. They monitor the patient’s response closely to adjust treatment plans as needed. Ongoing research continues to discover new pairings that improve outcomes and help more patients live longer, healthier lives.

Resistance and Comparative Treatments

Resistance to Therapy

Targeted therapies do not always work forever. Over time, some cancers find ways to grow despite treatment. New mutations in important genes like KRAS or other biological changes inside the tumor often cause this resistance. When this happens, the cancer stops responding the way it did at first. Researchers continue to explore new strategies, including new types of targeted treatments and combination therapies, to stay ahead of these changes and offer better options to patients.

Comparative Studies

Finding the best targeted therapy for each patient plays a critical role in treatment success. Many studies compare different therapies in people whose metastatic colorectal cancer no longer responds to chemotherapy. Each targeted treatment offers different strengths depending on the patient’s genetic profile and how the cancer behaves. Doctors use these comparisons to guide decisions and improve each patient’s chance of a better outcome by choosing the most effective available option.

Combination Approaches

Combining two or more targeted treatments gives doctors another way to overcome resistance. Some therapies work better when used together because they attack the cancer from different angles. Research teams continue to test different combinations to find the right balance between stronger results and manageable side effects. This strategy helps extend the benefits of targeted therapy for more patients.

Personalized Treatment Plans

Personalized treatment plans allow doctors to match each patient with the most effective therapy. They rely on detailed genetic testing and a deep understanding of the tumor’s behavior. By studying each patient’s unique cancer profile, doctors can recommend therapies that have a better chance of success. This approach leads to more targeted care, fewer side effects, and better results over time.

Conclusion

Targeted therapy for colorectal cancer represents a huge step forward in cancer treatment. By focusing on genes like KRAS mutated or BRAF mutations, blocking the vascular endothelial growth factor, and boosting the immune system, doctors offer hope to patients who once had few options. New therapies are reshaping the landscape and providing opportunities for better outcomes.

Find Expert Targeted Therapy for Colorectal Cancer at Onco Life Centre

If you or a loved one is considering targeted therapy for advanced colorectal cancer, Onco Life Centre in Kuala Lumpur is ready to support you. Our experienced team offers personalized cancer care, using the latest targeted therapies and diagnostic tools to create a treatment plan tailored to your specific needs. We are committed to providing compassionate, high-quality care to help you achieve the best possible outcome.

📞 Contact Us:

Phone: +60 12-399 3260

Office: +60 3 2242 3260

Email: info@oncolifecentre.com

Your Journey

Start Your Recovery

Our dedicated Patient Navigator will assist you with appointment scheduling. Contact us at +6012-3993260 (Call or Whatsapp ).

First Consultation

On appointment day, bring along all the medical reports and your identity documents, ie. identity card or passport. Our team will help you organize the medical reports for our oncologist to review. Our oncologist will discuss the treatment plan with you. Tele-consult is available for overseas patients.

Treatment Day

Come to our center on an agreed date and time for the treatment. Our team will take good care of you. You will be discharged on the same day. Yes, you will get to go home after every treatment visit as no overnight admission is required.

Stay on Track

Our dedicated patient navigator will be following up with you post treatment to check on your condition, to ensure that you are doing well. You will receive a reminder message on your phone for the next appointment date.

Dr. Christina Ng Van Tze

Consultant Medical Oncologist
Medical Director
MBBS (Melb) FRACP (Aus)

Monday - Friday : 08:00 AM TO 06:00 PM

Saturday : 08:00 AM TO 02:00 PM

D. Joseph K. Joseph

Consultant Medical Oncologist
MBBCH, BAO (IRE) MRCP (UK)

Wednesday : 08:00 AM TO 12:00 PM

Friday : 08:00 AM TO 12:00 PM

Advocacy Programs

Dr. Christina Ng Represents Onco Life Centre at ESMO 2025

Hello, I’m Dr. Christina Ng Van Tze, a Consultant Medical Oncologist and Medical Director at Onco Life Centre, as well as the Founder President of Empowered The Cancer Advocacy Society of Malaysia. Throughout my career, I have been passionate about advancing personalized cancer treatment, strengthening community advocacy, and expanding access to high-quality care for patients across Malaysia.

Attending the ESMO Congress 2025 in Berlin was both inspiring and energizing. Representing Onco Life Centre, our dedicated medical centre in Malaysia, I stood among global leaders committed to shaping the future of oncology. This year’s congress was filled with remarkable scientific breakthroughs, thoughtful discussions, and a renewed sense of purpose as we work toward better outcomes and better lives for our patients.

A Global Gathering Focused on Precision Cancer Care

ESMO 2025 brought together thousands of clinicians, researchers, and advocates from around the world. What made this year particularly exciting was the strong emphasis on precision medicine, from cancer genetics and molecular profiling to advanced imaging and AI-powered diagnostic tools. These advancements are aligning closely with the work we do at Onco Life Centre, where patient individuality and tumor biology guide our treatment decisions.

Throughout the congress, many experts highlighted the importance of understanding each patient’s tumor in greater depth. Whether through genomic sequencing, circulating tumor DNA, or radiomic analyses, the oncology community is moving firmly toward personalized strategies. As someone who has long championed individualized care, I found these sessions especially meaningful.

Key Scientific Sessions That Inspired Me

One of the standout presentations was the evERA BC trial, a major study evaluating the combination of giredestrant, an oral SERD, with an mTOR inhibitor drug in hormone receptor-positive breast cancer. The results showed a significant improvement in progression-free survival, especially in tumors driven by ESR1 mutations. For patients who have progressed on CDK4/6 inhibitors, this combination may become an essential addition to our treatment toolbox.

This study also supports a larger movement within oncology—creating thoughtful, layered treatment plans that address resistance pathways and extend the time patients can remain on endocrine-based therapies. It’s a direction that can profoundly benefit Malaysian women, many of whom are diagnosed at younger ages or have aggressive tumor profiles.

Insights from the thoracic oncology sessions were equally impactful. Advances in lung cancer, including AI-driven pathology models, updated ALK-targeted treatment strategies, and ctDNA-guided therapy adjustments, reminded me just how quickly this field is evolving. Given the increasing prevalence of lung cancer in Malaysia, especially among non-smokers and women, these developments hold tremendous value for our community.

The Role of AI in Transforming Clinical Practice

One major theme across the congress was the integration of artificial intelligence into clinical decision-making. Researchers demonstrated how AI models can analyze pathology slides, radiology images, and genomic data to predict which patients are more likely to respond to immunotherapy or targeted treatment. These tools help us avoid ineffective therapies and guide patients toward options with the most tremendous potential.

At Onco Life Centre, we have been exploring the use of digital technologies to streamline assessments and enhance patient monitoring. Seeing the global oncology community embrace these tools assures me that we are moving in the right direction. I hope that AI will continue to improve early detection, refine treatment selection, and ultimately support better survival outcomes for Malaysian patients.

Representing Onco Life Centre on the International Stage

Representing Onco Life Centre at an event of this scale was a true honor. Our centre has always focused on delivering holistic, science-driven care, and it was wonderful to share our experiences with colleagues from around the world. I had meaningful conversations about challenges related to access to molecular testing globally, variability in treatment availability, and the need for stronger psycho-oncology support systems.

These interactions not only validated the work we do but also highlighted areas where we can continue to grow. Bringing international insights back to Malaysia ensures that our patients benefit from the same cutting-edge thinking shaping care in Europe, America, and beyond.

Bringing ESMO Insights Home to Malaysia

Returning from Berlin, I feel a renewed commitment to integrating the latest research into our daily practice. In the coming months, we aim to:

Enhance our use of molecular profiling for breast, lung, and gastrointestinal cancers
Expand ctDNA testing where appropriate to guide treatment decisions
Strengthen multidisciplinary discussions for complex cases
Continue investing in supportive care and psycho-oncology services
Provide patients and families with clearer, more personalized education about treatment choices

As a clinician, I believe that every advancement, no matter how technical, must ultimately translate into compassionate, human-centered care. This balance of science and empathy remains at the core of our mission.

A Future of Hope and Collaboration

ESMO 2025 reaffirmed what I’ve always believed: oncology is advancing rapidly, but meaningful progress relies on collaboration, continuous learning, and a deep commitment to patient care. I’m genuinely grateful for the opportunity to represent Onco Life Centre on this global platform. Being part of these critical conversations strengthens our mission to raise the standard of oncology in Malaysia. It ensures our patients benefit from the latest, most effective innovations in cancer care.

Moving forward, we will continue engaging with global partners, conducting meaningful advocacy through Empowered, and ensuring our patients receive the highest standard of personalized treatment.

Together, we can build a future where every individual facing cancer feels seen, supported, and empowered.

Onco Life Centre Wins 2025 Best Oncology Clinic in Malaysia

We are proud to share that Onco Life Centre has been named the Oncology Clinic and Treatment Centre of the Year in Malaysia at the GlobalHealth Asia-Pacific Awards 2025, held in Bangkok.

This prestigious recognition is a testament to our unwavering commitment to delivering personalized, compassionate, and cutting-edge cancer care to our patients. The award reflects not just our clinical excellence, but our dedication to safety, community outreach, and innovation in oncology services.

The GlobalHealth Asia-Pacific Awards celebrate leading healthcare institutions across the region. Winners are chosen based on a comprehensive evaluation of criteria such as:

Excellence and Innovation: Transforming healthcare delivery and patient outcomes through progressive medical practices.
Patient Safety: Upholding the highest standards to ensure safe, comfortable, and effective treatment environments.
Community Involvement: Actively engaging in public awareness, screening programs, and care for underprivileged communities.
Technology Adoption: Integrating advanced diagnostics, therapies, and digital tools to enhance every aspect of care.
Impact and Measurable Results: Demonstrating tangible improvements in cancer detection, treatment success, and patient well-being.
Adaptability and Preparedness: Being resilient and forward-thinking in the face of global health challenges.
Leadership and Vision: Cultivating a culture that prioritizes empathy, innovation, and ongoing education.

This award inspires us to continue raising the bar in oncology care—not only through medical advancements but by remaining deeply rooted in our advocacy mission: to serve, educate, and empower every cancer patient, especially those most in need.

We dedicate this achievement to our patients, survivors, caregivers, and the entire Onco Life Centre community. Your courage fuels our purpose. Together, we will continue the fight—because every life matters.